<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065466</url>
  </required_header>
  <id_info>
    <org_study_id>1312169092</org_study_id>
    <nct_id>NCT02065466</nct_id>
  </id_info>
  <brief_title>Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases</brief_title>
  <official_title>A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1.1. Primary Objectives&#xD;
&#xD;
      1. To determine if nab-paclitaxel and temozolomide can be combined with full dose of&#xD;
      bevacizumab for the therapy of patients with newly diagnosed brain metastases of metastatic&#xD;
      malignant melanoma.&#xD;
&#xD;
        -  To define the MTD of the combination (Phase I component).&#xD;
&#xD;
        -  To determine progression free survival (Phase II component). 1.2. Secondary Objectives&#xD;
&#xD;
             1. To separately evaluate the response rate and duration of both the brain and&#xD;
                extra-cranial systemic metastases.&#xD;
&#xD;
             2. To define the toxicity of the regimen.&#xD;
&#xD;
             3. To tabulate the toxicity of the radiotherapy to the brain and compare with known&#xD;
                toxicities of radiotherapy to the brain in melanoma and brain metastases.&#xD;
&#xD;
             4. To use the data generated to plan definitive controlled clinical trials of the&#xD;
                combination.&#xD;
&#xD;
             5. To determine the overall response rate (Phase II component).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerance Dose</measure>
    <time_frame>Beginning of Treatment to unstable disease or discontinuation (6 months)</time_frame>
    <description>To define the MTD of the combination (Phase I component).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Treatment to End of Follow-up (6 Months)</time_frame>
    <description>To determine progression free survival (Phase II component).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Baseline to end of follow-up (six months)</time_frame>
    <description>To determine the overall response rate (Phase II component).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nab-paclitaxel and temozolomide combined with full dose of bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant melanoma and clinical evidence of&#xD;
             metastatic disease to the brain. Mucosal and ocular melanomas are included.&#xD;
&#xD;
          -  Newly developed inoperable brain metastases without associated hemorrhage or midline&#xD;
             shift.&#xD;
&#xD;
          -  Inoperable or metastatic extra cranial stage III or IV disease.&#xD;
&#xD;
          -  Diagnostic quality MRI of the brain or if contraindicated then contrast CT scan of the&#xD;
             head performed within 28 days prior to registration.&#xD;
&#xD;
          -  Measurable metastases to the brain, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;10&#xD;
             mm in the brain MRI/CT scan.&#xD;
&#xD;
          -  CT scan chest, abdomen and pelvis or PET CT scan performed within 28 days of study&#xD;
             registration. For disease outside the brain, tumors must be &gt; 10 mm by CT scan.&#xD;
&#xD;
          -  Prior therapy allowed but no prior therapy with nab-paclitaxel, paclitaxel,&#xD;
             temozolomide, DTIC or bevacizumab.&#xD;
&#xD;
          -  Bevacizumab may not be initiated until 4 weeks after surgical resection or radiation&#xD;
             therapy completion.&#xD;
&#xD;
          -  Age 18 or older.&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy must have &lt; Grade 2 (per CTCAE 4.0) at the time of&#xD;
             registration.&#xD;
&#xD;
          -  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males must use an effective&#xD;
             contraception method during treatment and for three months after completing treatment.&#xD;
&#xD;
          -  ECOG Performance status 0-1.&#xD;
&#xD;
          -  Estimated life expectancy of greater than 2 months.&#xD;
&#xD;
          -  Patients must have adequate organ function as defined below (these must be evaluated&#xD;
             within 14 days prior to registration):&#xD;
&#xD;
          -  leukocytes &gt;3,000/mcL&#xD;
&#xD;
          -  absolute neutrophil count &gt;1,500/mcL&#xD;
&#xD;
          -  platelets &gt;100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) &lt;2.5 X institutional upper limit&#xD;
&#xD;
          -  Alkaline phosphatase &lt;2.5 X institutional upper limit&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 X institutional upper limit of normal (unless associated with&#xD;
             Gilbert's syndrome)&#xD;
&#xD;
          -  serum creatinine &lt; 1.5 mg/dL OR 1.5 x institutional normal&#xD;
&#xD;
          -  LDH there is no restriction&#xD;
&#xD;
          -  INR &lt;1.5 PTT WNL&#xD;
&#xD;
          -  Urine protein (UPC) ratio 1.0 OR&#xD;
&#xD;
          -  Urine dipstick for proteinuria. Urine dipstick for proteinuria ≥ 2+ (patients&#xD;
             discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a&#xD;
             24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be&#xD;
             eligible).&#xD;
&#xD;
          -  Able to render informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgical resection for brain metastases.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to bevacizumab, nab-paclitaxel or temozolomide.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring parenteral antibiotics, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, untreated cardiac arrhythmia and peripheral vascular&#xD;
             disease.&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 6 months prior to Day 1.&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to Day 1.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to study screening.&#xD;
&#xD;
          -  Serious, non-healed wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  History of hepatitis B, C or HIV.&#xD;
&#xD;
          -  Uncontrolled hypertension or chronic renal disease. No known bleeding diathesis.&#xD;
&#xD;
          -  Known hypersensitivity to human albumin.&#xD;
&#xD;
          -  Surgery within 4 weeks of study registration. Must be fully recovered and fully healed&#xD;
             from any prior surgery.&#xD;
&#xD;
          -  Patients having chemotherapy or extra cranial radiotherapy within 4 weeks prior to&#xD;
             study screening or those who have not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks prior to the completion of study screening.&#xD;
&#xD;
          -  Evidence of other concurrent active malignancy.&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
&#xD;
          -  Not be receiving any other investigational agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Cranmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

